Abstract
14 patients with classical or definite rheumatoid arthritis and a low number of E-rosette forming cells were given single doses of 5 mg and 50 mg of thymopoietin intravenously. Thymopoietin pentapeptide produced a dose-related sustained increase in E-rosette forming lymphocytes as shown by the decrease of thymopoietin dependent rosetting ratio. A single dose of 50 mg restored the number of E-rosette forming cells to normal after 12 h and this effect lasted 60 to 7 days. With the administration of 5 E-rosette forming cells markedly increased after 12 h and returned to the pretreatment level on the 2nd day. These immunokinetic data clarify some aspects of the clinical pharmacology of thymopoietin pentapeptide and must be considered for a rational schedule of treatment with the drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
